SCHEMBL19483602

SCHEMBL19483602

CCc1onc(C(=O)NCC(C)C)c1CO

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 2/20 0.49
MEN1 O00255 1/20 0.49
RAB9A P51151 7/20 0.44
HPGD P15428 4/20 0.44
NPC1 O15118 6/20 0.38
SMN1; SMN2 Q16637 4/20 0.38
HTT P42858 3/20 0.38
ALDH1A1 P00352 2/20 0.38
MAPT P10636 1/20 0.38
LMNA P02545 2/20 0.36
POLB P06746 1/20 0.36
HDAC4 P56524 1/20 0.36
TRPV1 Q8NER1 3/20 0.36
GAA P10253 1/20 0.36
HSD17B10 Q99714 1/20 0.36
MLYCD O95822 1/20 0.35
TAS1R3 Q7RTX0 1/20 0.35
TAS1R1 Q7RTX1 1/20 0.35
TAS1R2 Q8TE23 1/20 0.35
NPSR1 Q6W5P4 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17483069 0.91 KMT2A (0.51) KMT2AMEN1RAB9AHPGDNPC1
SCHEMBL19483597 0.87 KMT2A (0.48) KMT2AMEN1RAB9AHPGDNPC1
SCHEMBL19483587 0.87 MEN1 (0.37) KMT2AMEN1RAB9AHPGDNPC1
SCHEMBL19484148 0.85 KMT2A (0.46) KMT2AMEN1RAB9AHPGDNPC1
SCHEMBL19483583 0.82 KMT2A (0.51) KMT2AMEN1RAB9AHPGDNPC1
SCHEMBL17483132 0.82 KMT2A (0.48) KMT2AMEN1RAB9AHPGDNPC1
SCHEMBL19483598 0.80 TRPV1 (0.54) TRPV1TAS1R3TAS1R1TAS1R2
SCHEMBL19483589 0.80 KMT2A (0.49) KMT2AMEN1RAB9AHPGDNPC1
SCHEMBL17483053 0.79 KMT2A (0.51) KMT2AMEN1RAB9AHPGDNPC1
SCHEMBL19483593 0.79 KMT2A (0.48) KMT2AMEN1RAB9AHPGDNPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20170295789-A1 AMIDE COMPOUND AND USE OF SAME FOR NOXIOUS ARTHROPOD CONTROL SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2017-10-19 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170295789-A1 AMIDE COMPOUND AND USE OF SAME FOR NOXIOUS ARTHROPOD CONTROL OPRM1, TRPA1, L3MBTL3 KMT2A 1451/4885MEN1 4192/4885RAB9A 753/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.